In a word, the result that FoxP3+Tregs has no effect on the prognosis of patients with cholangiocarcinoma may be the result of the intertumoral heterogeneity of gallbladder carcinoma and cholangiocarcinoma, the negative immune feedback mechanism of FoxP3+Tregs and anti-inflammation. This evidence concerns the gene FOXP3 and gallbladder carcinoma.